Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ages.

Patients with multiple myeloma (MM) can experience diminished ... bolster immunity in this vulnerable population. The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Multiple myeloma is a rare type of blood cancer that forms in plasma cells, a white blood cell that makes antibodies and helps you fight infection. The cancer occurs when the plasma cells inside ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers report. The detailed insights into cancer ...

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

when used as second-line therapy for multiple myeloma. The results were featured at the American Society of Haematology (ASH) annual meeting and, according to GSK, "support the potential for ...

Rahul Banerjee is a physician-researcher who specializes in multiple myeloma, a blood cancer caused by plasma ... Content Committee, American Society for Transplantation and Cellular Therapy (ASTCT) ...

when used as second-line therapy for multiple myeloma. GSK isn't revealing the size of the OS improvement yet – it has promised to do so at the American Society for Haematology (ASH) conference ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma ...